| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
2 BF Research Institute Inc., Osaka 565-0873, Japan
3 Department of Bacteriology, Nagasaki University School of Medicine, Nagasaki, 852-8501, Japan
4 Department of Laboratory Medicine, Kumamoto University, Kumamoto 860-0081, Japan
Correspondence
Kensuke Ishikawa
kensuke{at}np.med.kyushu-u.ac.jp
Katsumi Doh-ura
doh-ura{at}mail.tains.tohoku.ac.jp
Diagnostic imaging probes have been developed to monitor cerebral amyloid lesions in patients with neurodegenerative disorders. A thioflavin derivative, 2-[4'-(methylamino)phenyl] benzothiazole (BTA-1) and a Congo red derivative, (trans, trans),-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB) are representative chemicals of these probes. In this report, the two chemicals were studied in transmissible spongiform encephalopathies (TSE). Both BTA-1 and BSB selectively bound to compact plaques of prion protein (PrP), not only in the brain specimens of certain types of human TSE, but also in the brains of TSE-infected mice when the probes were injected intravenously. The chemicals bound to plaques in the brains were stable and could be detected for more than 42 h post-injection. In addition, the chemicals inhibited abnormal PrP formation in a cellular model of TSE with IC50 values of 4 nM for BTA-1 and 1·4 µM for BSB. In an experimental mouse model, the intravenous injection of 1 mg BSB prolonged the incubation period by 14 %. This efficacy was only observed against the RML strain and not the other strains examined. These observations suggest that these chemicals bind directly to PrP aggregates and inhibit new formation of abnormal PrP in a strain-dependent manner. Both BTA-1 and BSB can be expected to be lead chemicals not only for imaging probes but also for therapeutic drugs for TSEs caused by certain strains.
Present address: Department of Prion Research, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
This article has been cited by other articles:
|
|
 |
|
  P. B. McIntosh, S. R. Martin, D. J. Jackson, J. Khan, E. R. Isaacson, L. Calder, K. Raj, H. M. Griffin, Q. Wang, P. Laskey, et al. Structural Analysis Reveals an Amyloid Form of the Human Papillomavirus Type 16 E1{wedge}E4 Protein and Provides a Molecular Basis for Its Accumulation J. Virol., August 15, 2008; 82(16): 8196 - 8203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kawasaki, K. Kawagoe, C.-j. Chen, K. Teruya, Y. Sakasegawa, and K. Doh-ura Orally Administered Amyloidophilic Compound Is Effective in Prolonging the Incubation Periods of Animals Cerebrally Infected with Prion Diseases in a Prion Strain-Dependent Manner J. Virol., December 1, 2007; 81(23): 12889 - 12898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. P. Lipscomb, R. Herve, K. Harris, H. Pinchin, R. Collin, and C. W. Keevil Amyloid-specific fluorophores for the rapid, sensitive in situ detection of prion contamination on surgical instruments J. Gen. Virol., September 1, 2007; 88(9): 2619 - 2626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Raymond, E. A. Olsen, K. S. Lee, L. D. Raymond, P. K. Bryant III, G. S. Baron, W. S. Caughey, D. A. Kocisko, L. E. McHolland, C. Favara, et al. Inhibition of Protease-Resistant Prion Protein Formation in a Transformed Deer Cell Line Infected with Chronic Wasting Disease J. Virol., January 15, 2006; 80(2): 596 - 604. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
